Alphabet partners with pharmaceutical companies seeking to develop medicines with AI

In a landmark development, the Isomorphic Labs, the pioneering biotechnology division of A, announced high-profile collaborations with pharmaceutical leaders Eli Lilly e Novartis. This partnership seeks to take advantage of the artificial intelligence Isomorphic's cutting-edge technology for the development of small molecule medicines aimed at targets that have not yet been revealed.

Companies Leverage AI in Dementia Treatment and Drug Development

Startups in Cambridgeshire, UK, are leveraging artificial intelligence (AI) to advance healthcare. Know more!

Emerging from the forefront of innovation in Google DeepMind and leveraging the collective expertise of Alphabet's diverse companies, Isommorphic Labs is on a mission to revolutionize the drug discovery landscape. The company's AI technology is designed to speed up the treatment and cure of diseases.

Committed to addressing some of the most challenging questions in biology, chemistry and medical research, Isomorphic Labs is pioneering new computational approaches to unravel complex scientific mysteries.

Read also

Material found by AI could reduce lithium use in batteries

An entirely new substance that could reduce the use of lithium in batteries has been discovered through artificial intelligence (AI) and supercomputing. Understand.